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asthma treatment as identified by international guidelines. It consists of seven items
(5 symptoms, rescue bronchodilator use and FEV1% of predicted normal). A
validation study suggested that in clinical studies measurement of FEV1 and
bronchodilator use may not be needed but this has never formally been tested in a
clinical trial. The aims of this analysis were (1) to examine the measurement
properties of three shortened versions of the ACQ (symptoms alone, symptoms plus
FEV1 and symptoms plus short-acting b2-agonist) and (2) to determine whether using
the shortened versions would alter the results of a clinical trial. In the randomised
trial, 552 adults completed the ACQ at baseline and after 13 and 26 weeks of
treatment. The analysis showed that the measurement properties of all four versions
of the ACQ are very similar. Agreement between the original ACQ and the reduced
versions was high (intraclass correlation coefficients: 0.94–0.99). Mean differences
between the ACQ and the shortened versions were less than 0.04 (on the 7-point
scale). Clinical trial results using the four versions were almost identical with the
mean treatment difference ranging from 0.09 (P ¼ 0:17), to 0.13 (P ¼ 0:07). For
interpretability, the minimal important difference for all four versions was close to
0.5. In conclusion, these three shortened versions of the ACQ can be used in large
clinical trials without loss of validity or change in interpretation.
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The Asthma Control Questionnaire (ACQ)1 was
developed and validated to measure the primaryed.
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international guidelines.2–5 They indicate that to
achieve good control, treatment should minimise
day and night time symptoms, activity limitation,
airway narrowing and rescue bronchodilator use
and thus reduce the risk of life-threatening
exacerbations and long-term morbidity. The im-
portance of including all aspects of control in the
assessment of individual patients was emphasised
by a recent factor analysis which showed that
clinical asthma is composed of distinct components
which are not closely correlated with each other.6
However, in some studies it may not be possible to
collect airway calibre or short-acting b2-agonists
data. Previous analysis of non-clinical trial data
suggested that when ACQ scores are analysed as
group data, the heterogeneity of the way in which
individual patients present with inadequate control
is lost in the estimation of the mean and the need
to measure each individual component of asthma
control may become unnecessary.7 In this analysis,
ACQ data from a clinical trial was used to evaluate
the measurement properties (reliability, respon-
siveness, validity and interpretability), of three
shortened versions of the ACQ. In addition, we have
examined whether the precision and accuracy of
estimating the effect of the intervention on asthma
control was maintained when the two questions
concerning airway calibre and short-acting b2-
agonists use were omitted from the trial analysis.Methods
Patients and study design
The analysis was conducted using the database
from a 26-week, randomised, clinical study in
which the combination of inhaled glucocorticoster-
oid plus long-acting, rapid-onset b2-agonist was
compared with the constituents taken separately.
Of the 586 adults randomised, all of whom required
inhaled steroids, 552 completed the ACQ and Mini
Asthma Quality of Life Questionnaire (MiniAQLQ)8
at baseline and after 13 and 26 weeks of treatment
(Table 1). Complete details of the study are
published elsewhere.9Table 1 Demographics and baseline values.
Number of patients 552
Mean age (range) years 44.7 (18–81)
Gender M/F 249/303
Mean FEV1% pred. (range) 87.9 (49.9–142.5)Asthma Control Questionnaire
Ninety-one asthma clinicians, who were members
of international asthma guideline committees,2–5
participated in the development of the ACQ.1 They
identified the seven items in the questionnaires as
being the most important for determining the
adequacy of asthma control. Patients are asked to
recall their experiences during the previous week
and to respond to the first six questions (nighttime
waking, symptoms on waking, activity limitation,
shortness of breath, wheeze and rescue short-
acting b2-agonist use) on a 7-point scale (0=no
impairment; 6=maximum impairment). Clinic staff
score FEV1% predicted pre-bronchodilator on a
similar 7-point scale. The items are equally
weighted and the ACQ score is the mean of the
seven items and therefore between 0 (well con-
trolled) and 6 (extremely poorly controlled). The
ACQ has been validated and has strong measure-
ment properties for use in both clinical practice
and clinical trials.1 In this analysis, three shortened
versions of the ACQ (symptoms alone (questions
1–5), symptoms plus FEV1 and symptoms plus short-
acting b2-agonist), were compared with the original
ACQ.
Mini Asthma Quality of Life Questionnaire
The MiniAQLQ8 consists of 15 questions in four
domains (symptoms, activity limitations, emotional
function and environmental stimuli) and measures
the problems that adults with asthma find most
troublesome in their day-to-day lives. Patients
respond to each question on a 7-point scale from
7=‘not bothered at all’ to 1=‘extremely bothered’.
All questions are equally weighted and the overall
score is the mean of the 15 responses. The
MiniAQLQ has strong evaluative and discriminative
measurement properties and the minimal impor-
tant difference is 0.5 on the 7-point scale.8
Statistical analysis
Throughout the analysis, the original 7-item ACQ
has been considered the gold standard (reference)
against which the shortened versions have been
compared (criterion validity). Data collected at
baseline were used to determine differences
(paired t-test), concordance (intraclass correlation
coefficient) and internal consistency (Cronbach’s
alpha).
For all four instruments, test–retest reliability
has been estimated as the within-subject standard
deviation and related to the total standard
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(ICC) using data from patients who remained stable
(defined as having a change in MiniAQLQ score
o0.5) between weeks 13 and 26. This statistic also
provides evidence of the instrument’s ability to
discriminate between patients of different levels of
impairment. Responsiveness (sensitivity to change)
of the instruments was evaluated by comparing
change scores between baseline and week 26 and
by examining the clinical trial results. Both cross-
sectional and longitudinal construct validity have
been evaluated by comparing associations (Pearson
correlation coefficient) with MiniAQLQ. For inter-
pretability the change in ACQ scores that was
equivalent to a change in MiniAQLQ score of 0.5 was
calculated by regressing the change in ACQ scores
on change in MiniAQLQ scores, using a geometric
mean regression model.10 This method allows for
measurement errors in the independent (MiniAQLQ)
variable as well as the dependent (ACQ) variable.
The statistical package used was SAS version 8.2,
SAS Institute Inc., Cary, NC 27513, USA.Results
Criterion validity
At baseline the three shortened versions of the ACQ
provided mean data that was very concordant with
the original ACQ (ICCX0.94) (Table 2). Although
the ‘symptoms alone’ and ‘symptoms plus b2-
agonist’ versions were statistically different from
the original ACQ, the actual differences were trivial
(p0.04 where the minimal important difference
is approx. 0.5) and cannot be considered of
clinical importance. Internal consistencies of theTable 2 Shortened versions compared with the original
Instrument Mean score at
baseline
mean (SD)
Difference
between ACQ and
short versions at
baseline mean (SD)
P-value*
Change s
between
baseline
26 week
mean (SD
All questions (ACQ) 1.52 (0.82) n/a 0.51 (0
Symptoms alone 1.48 (0.93) 0.039 (0.29) 0.48 (0
p ¼ 0:0015
Symptoms plus FEV1 1.52 (0.87) 0.004 (0.14) 0.48 (0
p ¼ 0:50
Symptoms plus b2-agonist 1.48 (0.86) 0.037 (0.23) 0.52 (0
p ¼ 0:0002
SD, standard deviation; ICC, intraclass correlation coefficient.
*Paired t-test.shortened versions were very similar to those of the
original ACQ.
Reliability
Three hundred and eighty-one patients remained
stable between weeks 13 and 26 and demonstrated
reliability to be consistent and high (ICCX0.82) for
all four versions (Table 3).
Responsiveness
Change scores between baseline and 26 weeks for
all four versions were all very similar (0.48 to
0.52) (Table 2). However, the ‘symptoms alone’
and ‘symptoms plus FEV1’ versions were statisti-
cally different from the original but the difference
was trivial (p0.04) and cannot be considered of
clinical importance. The clinical trial analysis
comparing change in asthma control between
baseline and 26 weeks in the two treatment groups,
showed very similar results for all four versions
(Table 4). Taken in conjunction, these two analyses
provide evidence that responsiveness (sensitivity to
change) is very similar in the four versions.
Construct validity
Both cross-sectional and longitudinal correlations
with the MiniAQLQ were very similar for all four
versions (Table 5a and b). This evidence of
construct validity, taken in conjunction with the
criterion validity of the new versions (close
concordance with the original), provides strong
evidence that the new versions are measuring the
same construct as the original ACQ.ACQ (0=good control, 6=extremely poor control).
core
and
s
)
Difference between
change in ACQ and change
in short versions between
baseline and 26 weeks
mean (SD)
P-value*
Concordance
between ACQ and
short versions at
baseline ICC
Internal
consistency at
baseline
Cronbach’s
alpha
.76) n/a n/a 0.98
.87) 0.027 (0.23) 0.94 0.98
p ¼ 0:0072
.789) 0.033 (0.13) 0.99 0.97
po0:0001
.83) 0.011 (0.16) 0.96 0.98
p ¼ 0:12
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Table 3 Reliability (n ¼ 381).
Instrument Within-subject SD Between-subject SD ICC
All questions (ACQ) 0.25 0.62 0.83
Symptoms alone 0.30 0.71 0.82
Symptoms plus FEV1 0.26 0.65 0.84
Symptoms plus b2-agonist 0.29 0.67 0.82
SD, standard deviation; ICC, intraclass correlation coefficient.
Table 4 Clinical trial results.
Instrument Improvement
on treatment A
mean (SD)
Improvement
on treatment B
mean (SD)
Change on A–change on B
P-value
All questions (ACQ) 0.54 (0.68) 0.45 (0.68) 0.09
p ¼ 0:17
Symptoms alone 0.52 (0.78) 0.40 (0.78) 0.13
p ¼ 0:07
Symptoms plus FEV1 0.51 (0.70) 0.41 (0.70) 0.10
p ¼ 0:11
Symptoms plus b2-agonist 0.55 (0.74) 0.45 (0.74) 0.10
p ¼ 0:13
SD, standard deviation.
Table 5 Construct validity (Pearson correlation coefficients)
a) Cross-sectional (baseline)
Instrument All questions (ACQ) Symptoms alone Symptoms + FEV1 Symptoms +
b2-agonist
MiniAQLQ 0.72 0.77 0.72 0.76
b) Longitudinal (baseline - 26 weeks)
Instrument Change in all
questions (ACQ)
Change in
symptoms alone
Change in
symptoms + FEV1
Change in symptoms +
b2-agonist
Change in
MiniAQLQ
0.74 0.75 0.74 0.75
E.F. Juniper et al.556Interpretability
The minimal important difference for all four
versions was close to 0.5. The geometric mean
regression values and estimated standard errors
were: All questions (ACQ): 0.46 (0.013); symptoms
alone: 0.52 (0.015); symptoms+FEV1: 0.46 (0.014)
and symptoms+b2-agonist: 0.49 (0.014).Discussion
The results of this analysis provide strong evidence
that when the FEV1 and b2-agonist questions are
omitted from the original ACQ in clinical trials, the
results generated will be very similar to those that
would have been generated if the complete
questionnaire had been used. The measurement
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consistency, construct validity and interpretability)
of the three shortened versions of the ACQ are very
similar to those of the original.
Although it is ideal to use the complete 7-item
ACQ so that the individual components of clinical
asthma may be examined separately, there are a
number of situations in which it is not feasible to
collect airway calibre or rescue short-acting b2-
agonist data. In epidemiological surveys, not only
will some patients not have access to bronchodila-
tors but there may be no means of measuring
airway calibre. Although most pharmaceutical
company trials are conducted in locations where
both airway calibre and inhaled b2-agonist use can
be recorded, other non-pharmaceutical interven-
tions (e.g. education, exercise) may have to be
evaluated under less favourable conditions. In
addition, phone, post and internet completion of
the ACQ may have to be done without access to a
home spirometer or peak flow meter.
The advent of a new rapid and long-acting
inhaled b2-agonist, formoterol, has given a new
challenge to the assessment of asthma control. All
the original guidelines were drawn up when only
short-acting b2-agonists were used as rescue med-
ication.2–5 However, recent studies with formoterol
have shown that it can be used both as regular
maintenance and a rescue intervention in patients
already taking an inhaled steroid.11,12 Therefore
the optimum method for incorporating its use in the
estimation of asthma control and also its scoring in
the ACQ have not yet been established. This study
has shown that this poses no problem for the
assessment of asthma control in clinical trials of
rapid and long-acting inhaled b2-agonists because
the bronchodilator question can be omitted.
We used a recognised ‘anchor-based’ method to
estimate the minimal important difference of the
ACQ. This is a clinical rather than statistical
approach and links changes in the new instrument
to clinically meaningful changes in a well-estab-
lished instrument or changes in recognised health
states.13 Although not measuring the same con-
structs (concepts), the new and the established
instruments are required to be fairly closely
correlated so that regression models can be used.
In this study, the correlation of r ¼ 0:74 or higher
between change in ACQ and change in MiniAQLQ
allowed us to estimate the minimal important
differences for the ACQ using the geometric mean
model. A previous study which used a different
anchor-based approach (global rating), showed
that a single clinician estimated the minimal
important difference for the ACQ to be 0.54.14
With two different methods yielding similar results,we can be confident that the minimal important
difference for the four versions of the ACQ is close
to 0.5.
A recent factor analysis showed that clinical
asthma has four distinct components: daytime
symptoms plus daytime b2-agonist use, nighttime
symptoms plus nighttime b2-agonist use, airway
calibre and quality of life.6 In other words, daytime
b2-agonist use correlates closely with daytime
symptoms and nighttime use correlates closely
with nighttime symptoms. This suggests that omis-
sion of b2-agonist use may be less serious in the
estimation of asthma control in individual patients
than the omission of airway calibre which does not
correlate well with either daytime or nighttime
symptoms. However, until this has been investi-
gated more thoroughly, clinicians looking after
individual patients should endeavour to measure
all the criteria identified in current guidelines2–5,15
namely symptoms, activity limitations, airway
calibre and rescue bronchodilator use.
In conclusion, this study has shown that the
results and interpretation of clinical studies will not
be affected if the questions concerning airway
calibre and rescue bronchodilator use are omitted
from the ACQ. However, these results only apply to
group analyses and should not be applied to
individual patients. Patients with poor perception
of airway narrowing may have inadequately con-
trolled asthma missed because they are asympto-
matic and use no rescue bronchodilators. To
minimise the risk of severe exacerbations in
individual assessments, all components of asthma
control should be measured.References
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